/GRCE
GRCE Stock - Grace Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.40+1.49%
+$0.05 (+1.49%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GRCE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.37 – $3.43
TARGET (TP)$3.91
STOP LOSS$3.13
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.60
52W High$4.68
52W Low$1.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $196,000 |
| Gross Profit | N/A | $-11,000 | N/A | N/A | $120,000 |
| Gross Margin | N/A | N/A | N/A | N/A | 61.2% |
| Operating Income | $-16,679,000 | $-11,312,000 | $-52,155,000 | $-15,589,000 | $-16,419,000 |
| Net Income | $-9,568,000 | $-12,853,000 | $-42,429,000 | $-9,819,000 | $-19,678,000 |
| Net Margin | N/A | N/A | N/A | N/A | -10039.8% |
| EPS | $-0.79 | $-1.73 | $-5.71 | $-1.60 | $-7.98 |
Company Overview
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 252.9% Upside
Now
$12
Low
$12
Average
$12
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 2nd 2025 | TD Cowen | Initiation | Buy | $12 |
Earnings History & Surprises
GRCEBeat Rate
33%
Last 12 quarters
Avg Surprise
-20.1%
EPS vs Estimate
Beats / Misses
4/7
1 met exactly
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
-4.4%
$-0.24vs$-0.23
Q2 24
+48.6%
$-0.18vs$-0.35
Q3 24
+14.3%
$-0.24vs$-0.28
Q4 24
0.0%
$-0.33vs$-0.33
Q1 25
-8.3%
$-0.26vs$-0.24
Q2 25
-5.0%
$-0.21vs$-0.20
Q3 25
+4.5%
$-0.21vs$-0.22
Q4 25
-25.0%
$-0.15vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 12, 2026 | $-0.09 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q2 2025 | Jun 23, 2025 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.33 | $-0.33 | 0.0% | = MET |
Q3 2024 | Aug 9, 2024 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q2 2024 | Jun 21, 2024 | $-0.35 | $-0.18 | +48.6% | ✓ BEAT |
Q1 2024 | Feb 12, 2024 | $-0.23 | $-0.24 | -4.4% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.26 | $-0.32 | -23.0% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.28 | $-0.41 | -45.9% | ✗ MISS |
Q2 2023 | Jun 23, 2023 | $-0.84 | $-2.89 | -244.2% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-0.74 | $-0.39 | +47.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | — | $-0.48 | — | — |
Q3 2022 | Aug 11, 2022 | — | $-0.48 | — | — |
Q2 2022 | Jun 21, 2022 | — | $-0.46 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-0.40 | — | — |
Q4 2021 | Nov 10, 2021 | — | $0.14 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.58 | — | — |
Q2 2021 | Jun 22, 2021 | — | $-1.32 | — | — |
Latest News
Grace Therapeutics Q2 EPS $(0.06) Beats $(0.18) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 01:12 PM
Grace Therapeutics Secures ~$4M Through Common Warrant Exercises Issued In Previously Issued Private Placement
📈 PositiveBenzinga•Oct 23, 2025, 12:02 PM
Grace Therapeutics Presents Results From Pivotal Phase 3 STRIVE-ON Safety Trial Of GTx-104 In aSAH At 2025 Neurocritical Care Society Annual Meeting
➖ NeutralBenzinga•Sep 22, 2025, 12:06 PM
Grace Therapeutics Awarded Patent Titled "Nimodipine Parenteral Administration" From U.S. Patent and Trademark Office. Patent Covers Dosing Regimen For Intravenous Nimodipine Used In Phase 3 Strive-On Safety Trial For GTX-104
📈 PositiveBenzinga•Sep 18, 2025, 12:38 PM
Grace Therapeutics Granted US Patent Covering An I.V. Dosing Regimen For GTx-104
📈 PositiveBenzinga•Sep 18, 2025, 12:38 PM
FDA Accepts Grace Therapeutics' New Drug Administration For GTx-104 For Formal Review
📈 PositiveBenzinga•Aug 27, 2025, 12:03 PM
Frequently Asked Questions about GRCE
What is GRCE's current stock price?
Grace Therapeutics, Inc. (GRCE) is currently trading at $3.40 per share. The stock has moved +1.49% today.
What is the analyst price target for GRCE?
No analyst price targets are currently available for this stock.
What sector is Grace Therapeutics, Inc. in?
Grace Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GRCE's market cap?
Grace Therapeutics, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does GRCE pay dividends?
No, Grace Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVC
ABVC BioPharma, Inc.
$2.19
Mkt Cap: $0.0B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
CALC
CalciMedica, Inc.
$6.35
Mkt Cap: $0.1B
LTRN
Lantern Pharma Inc.
$3.26
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
RNXT
RenovoRx, Inc.
$0.93
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to GRCE for comparison